MDM2抑制剂AMG 232联合或不联合曲美替尼治疗复发难治急性髓系白血病的1b期研究
这项开放标签1期研究评估了口服选择性MDM2抑制剂AMG 232在复发/难治急性髓系白血病中的安全性、药代动力学和最大耐受剂量。AMG 232单药(60-960 mg,7天给药/停7天)或60 mg联合曲美替尼2 mg给药;36例患者全部接受AMG 232,单药组未发生DLT,360 mg为最高测试剂量,更高剂量因胃肠道不良事件停止爬坡。AMG 232显示线性药代动力学、靶点效应和初步临床活性。
要点
- 单药组未发生DLT,360 mg为最高测试剂量,更高剂量因胃肠道不良事件停止爬坡。
- 30例可评估患者中1例完全缓解、4例形态学无白血病状态、1例部分缓解。
核心结论
- AMG 232在较高剂量下与胃肠道不良事件相关,但具有可接受的药代动力学、靶点效应和值得进一步研究的初步临床活性。
研究设计与样本
- 开放标签1期研究,评估AMG 232单药(60、120、240、360、480或960 mg,每日口服,7天给药/停7天)或AMG 232 60 mg联合曲美替尼2 mg在复发/难治急性髓系白血病患者中的安全性、药代动力学和最大耐受剂量;共36例患者全部接受AMG 232。
主要发现
- 常见治疗相关不良事件(任何级别)包括恶心(58%)、腹泻(56%)、呕吐(33%)和食欲下降(25%)。
- AMG 232呈线性药代动力学,与曲美替尼联合给药不影响其药代动力学。
- 治疗期间血清巨噬细胞抑制因子-1及骨髓BAX、PUMA、P21和MDM2表达升高。
- 30例可评估患者中1例完全缓解、4例形态学无白血病状态、1例部分缓解;13例TP53野生型患者中4例(31%)缓解,3例TP53突变型患者中0例(0%)缓解。
关键数值与推荐
- AMG 232单药剂量递增至360 mg为最高测试剂量,更高剂量因胃肠道不良事件停止爬坡。
临床怎么用
- AMG 232在复发/难治急性髓系白血病中显示出可接受的药代动力学、靶点效应和初步临床活性,值得进一步研究。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This open-label, phase 1 study evaluated the safety, pharmacokinetics, and maximum tolerated dose of AMG 232, an investigational oral, selective mouse double minute 2 homolog inhibitor in relapsed/refractory acute myeloid leukemia (AML). AMG 232 was administered orally once daily for 7 days every 2 weeks (7 on/off) at 60, 120, 240, 360, 480, or 960 mg as monotherapy (arm 1) or at 60 mg with trametinib 2 mg (arm 2). Dose-limiting toxicities (DLTs), adverse events (AEs), pharmacokinetics, clinical and pharmacodynamic response, and expression of p53 target genes were assessed. All 36 patients received AMG 232. No DLTs occurred in arm 1, and 360 mg was the highest test dose; dose escalation was halted due to gastrointestinal AEs at higher doses. One of ten patients in arm 2 had a DLT (grade 3 fatigue); 60 mg was the highest dose tested with trametinib. Common treatment-related AEs (any grade) included nausea (58%), diarrhea (56%), vomiting (33%), and decreased appetite (25%). AMG 232 exhibited linear pharmacokinetics unaffected by coadministration with trametinib. Serum macrophage inhibitor cytokine-1 and bone marrow expression of BAX, PUMA, P21, and MDM2 increased during treatment. Of 30 evaluable patients, 1 achieved complete remission, 4 had morphologic leukemia-free state, and 1 had partial remission. Four of 13 (31%) TP53-wild-type patients and 0 of 3 (0%) TP53-mutant patients were responders. AMG 232 was associated with gastrointestinal AEs at higher doses but had acceptable pharmacokinetics, on-target effects, and promising clinical activity warranting further investigation in patients with relapsed/refractory AML. This trial was registered at www.clinicaltrials.gov as #NCT02016729.
引用
- Erba HP, Becker PS, Shami PJ, et al. Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. Blood Adv. 2019. PMID: 31253596. doi:10.1182/bloodadvances.2019030916
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。